This editorial summarizes a research topic focused on innovative therapies for rare inflammatory skin diseases such as lichen planus, lichen sclerosus, granulomatous dermatoses, and hidradenitis suppurativa.[1] Despite successes in the treatment of common conditions such as psoriasis and atopic dermatitis, where research translation has led to biologics and small molecules, these rare diseases still lack effective treatment options.[1][2] In 2026, 14 targeted drugs are approved by the European Medicines Agency (EMA) for moderate to severe plaque psoriasis in adults.[2] New laboratory techniques, such as single-cell sequencing and spatial omics, provide deep insights into inflammatory processes in both affected and unaffected skin.[1][2] The editors invite contributions from basic research to clinical applications, including lichenoid dermatoses, cutaneous lupus erythematosus, connective tissue diseases, neutrophilic dermatoses, granulomatous diseases, and hidradenitis suppurativa.[1] It includes original studies, reviews, hypotheses, perspectives, and case studies, with the goal of accelerating translation from the laboratory to practice.[1] Examples include baricitinib, rituximab, and tacrolimus multitarget therapy in anti-MDA5 dermatomyositis, which improved survival over conventional therapy, and ruxolitinib in thrombocytotic dermatomyositis.[2][4] The topic serves as a platform for sharing preliminary experiences with innovative treatments.[1]